Tenax Therapeutics Inc expected to post a loss of $1.39 a share - Earnings Preview

Tenax Therapeutics

08/11/2024 22:15

* Tenax Therapeutics Inc  TENX.OQ   TENX.O  is expected
to show no
change in quarterly revenue when it reports  results on November
11 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Tenax Therapeutics Inc
is for
a loss of $1.39 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tenax
Therapeutics Inc is $16.00​, above​ its last closing price
of $4.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.99       -1.98      -1.83     Beat    7.8
 Jan. 1 0001   -2.48       -2.40      -3.12     Missed  -30
 Dec. 31 2023  -8.11       -8.14      -12.98    Missed  -59.4​
 Sep. 30 2023  -4.80       -7.20      -6.40     Beat    11.1
 ​​Jun.        -7.90       -8.00      -4.00     Beat    50
 30 2023                                                
 Mar. 31 2023  -29.60      -29.60     -12.00    Beat    59.5​
 Dec. 31 2022  -1.82       -1.82      -1.38     Beat    24.1
               hundred     hundred    hundred           
 Sep. 30 2022  -1.68       -1.68      -1.76     Missed  -4.8
               hundred     hundred    hundred           
 This summary was machine generated November 8 at 22:15 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)